mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2019-3-4-9mrj-927Research ArticleЛЕКЦИЯLECTUREМультиморбидность в ревматологии. От комплексной оценки болезни – к оценке комплекса болезнейMultimorbidity in rheumatology. From comprehensive assessment of disease to evaluation of a set of diseasesЛилаА. М.LilaA. M.

Лила Александр Михайлович.

115522, Москва, Каширское шоссе, 34А; 2125993, Москва, ул. Баррикадная, 2/1, стр. 1.

Aleksandr Mikhailovich Lila.

134A, Kashirskoe Shosse, Moscow 115522; 22/1, Barrikadnaya St., Build. 1, Moscow 125993.

amlila@mail.ruГордеевА. В.GordeevA. V.

115522, Москва, Каширское шоссе, 34А.

134A, Kashirskoe Shosse, Moscow 115522.

ОлюнинЮ. А.OlyuninYu. A.

115522, Москва, Каширское шоссе, 34А.

134A, Kashirskoe Shosse, Moscow 115522.

ГалушкоЕ. А.GalushkoE. A.

115522, Москва, Каширское шоссе, 34А.

134A, Kashirskoe Shosse, Moscow 115522.

Научно-исследовательский институт ревматологии им. В.А. Насоновой; Российская медицинская академия непрерывного профессионального образования Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Department of Rheumatology, Russian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaRussian FederationНаучно-исследовательский институт ревматологии им. В.А. НасоновойРоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation20191709201913349Copyright © Лила А.М., Гордеев А.В., Олюнин Ю.А., Галушко Е.А., 20192019Лила А.М., Гордеев А.В., Олюнин Ю.А., Галушко Е.А.Lila A.M., Gordeev A.V., Olyunin Y.A., Galushko E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/927

Всемирная организация здравоохранения относит к основным неинфекционным заболеваниям кардиоваскулярные, онкологические, хронические респираторные болезни, а также сахарный диабет и некоторые другие нозологии, включая психическую и скелетно-мышечную патологию. Считается, что они представляют собой главную проблему здравоохранения XXI в. При этом у одного пациента часто встречается сочетание нескольких ассоциированных с возрастом хронических заболеваний, которые развиваются одновременно или последовательно. Ведение таких больных требует интегрального подхода, ориентированного на мультиморбидный характер патологии. В отличие от определения коморбидных нарушений, которое предполагает выделение основного и сопутствующих заболеваний, концепция мультиморбидности таких градаций не предусматривает и трактует имеющиеся у пациента хронические заболевания как равнозначные.

The World Health Organization assigns cardiovascular diseases, cancers, chronic respiratory diseases, as well as diabetes mellitus and some other nosological entities, including mental and musculoskeletal disorders, to main non-communicable diseases. These are considered to be a major public health challenge of the 21st century. In this case, one patient frequently has a set of several age-related chronic diseases that develop simultaneously or sequentially. The management of these patients requires an integrated approach based on the multimorbid nature of pathology. Unlike the definition of comorbidities, which assumes to identify the underlying and related diseases, the concept of multimorbidity of such gradations fails to provide and interprets a patient's chronic diseases as equivalent.

мультиморбидностькоморбидностьсмертностьревматические заболеваниялечениеmultimorbiditycomorbiditymortalityrheumatic diseasestreatmentReferencesНасонов ЕЛ, Гордеев АВ, Галушко ЕА. Ревматические заболевания и мультиморбидность. Терапевтический архив. 2015;(5):4-9.Nasonov EL, Gordeev AV, Galushko EA. Rheumatic diseases and multimorbidity. Terapevticheskii arkhiv. 2015;(5):4-9. (In Russ.).Manfredi G, MidBo L, Paul C, et al. Prevalence of frailty status among the European elderly population: Findings from the Survey of Health, Aging and Retirement in Europe. Geriatr GerontolInt. 2019 May 30. doi: 10.1111/ggi.13689. [Epub ahead of print]Manfredi G, MidBo L, Paul C, et al. Prevalence of frailty status among the European elderly population: Findings from the Survey of Health, Aging and Retirement in Europe. Geriatr GerontolInt. 2019 May 30. doi: 10.1111/ggi.13689. [Epub ahead of print]Weng NP Aging of the immune system: how much can the adaptive immune system adapt? Immunity. 2006 May;24(5):495-9.Weng NP Aging of the immune system: how much can the adaptive immune system adapt? Immunity. 2006 May;24(5):495-9.Boots AM, Maier AB, Stinissen P, et al. The influence of ageing on the development and management of rheumatoid arthritis. Nat Rev Rheumatol. 2013 Oct;9(10):604-13. doi: 10.1038/nrrheum.2013.92Boots AM, Maier AB, Stinissen P, et al. The influence of ageing on the development and management of rheumatoid arthritis. Nat Rev Rheumatol. 2013 Oct;9(10):604-13. doi: 10.1038/nrrheum.2013.92Goronzy JJ, Weyand CM. Aging, autoimmunity and arthritis: T-cell senescence and contraction of T-cell repertoire diversity - catalysts of autoimmunity and chronic inflammation. Arthritis Res Ther. 2003;5(5): 225-34. Epub 2003 Aug 8.Goronzy JJ, Weyand CM. Aging, autoimmunity and arthritis: T-cell senescence and contraction of T-cell repertoire diversity - catalysts of autoimmunity and chronic inflammation. Arthritis Res Ther. 2003;5(5): 225-34. Epub 2003 Aug 8.Michaud M, Balardy L, Moulis G, et al. Proinflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc. 2013 Dec;14(12):877-82. doi: 10.1016/j.jamda.2013.05.009.Michaud M, Balardy L, Moulis G, et al. Proinflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc. 2013 Dec;14(12):877-82. doi: 10.1016/j.jamda.2013.05.009.Daien CI, Tubery A, Beurai-Weber M, et al. Relevance and feasibility of a systematic screening of multimorbidities in patients with chronic inflammatory rheumatic diseases. Joint Bone Spine. 2019 Jan;86(1):49-54. doi: 10.1016/j.jbspin.2018.03.016.Daien CI, Tubery A, Beurai-Weber M, et al. Relevance and feasibility of a systematic screening of multimorbidities in patients with chronic inflammatory rheumatic diseases. Joint Bone Spine. 2019 Jan;86(1):49-54. doi: 10.1016/j.jbspin.2018.03.016.Гордеев АВ, Галушко ЕА, Насонов ЕЛ. Концепция мультиморбидности в ревматологической практике. Научно-практическая ревматология. 2014;52(4):362—5. doi: 10.14412/1995-4484-2014-362-365Gordeev AV, Galushko EA, Nasonov EL. The concept of multimorbidity in rheumatologic practice. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(4):362—5. (In Russ.). doi: 10.14412/1995-4484-2014-362-365Le Reste JY, Nabbe P, Manceau B, et al. The European General Practice Research Network presents a comprehensive definition of multimorbidity in family medicine and long term care, following a systematic review of relevant literature. J Am Med Dir Assoc. 2013 May;14(5):319-25. doi: 10.1016/j.jamda.2013.01.001.Le Reste JY, Nabbe P, Manceau B, et al. The European General Practice Research Network presents a comprehensive definition of multimorbidity in family medicine and long term care, following a systematic review of relevant literature. J Am Med Dir Assoc. 2013 May;14(5):319-25. doi: 10.1016/j.jamda.2013.01.001.Sattar N, Mclnnes IB. Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol. 2005 May;17(3):286-92.Sattar N, Mclnnes IB. Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol. 2005 May;17(3):286-92.Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012 Jul 7;380(9836):37-43. doi: 10.1016/S0140-6736(12)60240-2.Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012 Jul 7;380(9836):37-43. doi: 10.1016/S0140-6736(12)60240-2.Uijen AA, van de Lisdonk EH. Multimorbidity in primary care: prevalence and trend over the last 20 years. Eur J Gen Pract. 2008;14 Suppl 1:28-32. doi: 10.1080/13814780802436093.Uijen AA, van de Lisdonk EH. Multimorbidity in primary care: prevalence and trend over the last 20 years. Eur J Gen Pract. 2008;14 Suppl 1:28-32. doi: 10.1080/13814780802436093.Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitor-ing: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014 Jan;73(1):62-8. doi: 10.1136/annrheumdis-2013-204223Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheuma-toid arthritis and evaluation of their monitor-ing: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014 Jan;73(1):62-8. doi: 10.1136/annrheumdis-2013-204223Raterman HG, Levels H, Voskuyl AE, et al. HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab. Ann Rheum Dis. 2013 Apr;72(4):560-5. doi: 10.1136/annrheumdis-2011-201228.Raterman HG, Levels H, Voskuyl AE, et al. HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab. Ann Rheum Dis. 2013 Apr;72(4):560-5. doi: 10.1136/annrheumdis-2011-201228.Jamnitski A, Symmons D, Peters MJ, et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis. 2013 Feb;72(2):211-6. doi: 10.1136/annrheumdis-2011-201194.Jamnitski A, Symmons D, Peters MJ, et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis. 2013 Feb;72(2):211-6. doi: 10.1136/annrheumdis-2011-201194.Murray SG, Yazdany J, Kaiser R, et al. Cardiovascular disease and cognitive dysfunction in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012 Sep;64(9):1328-33. doi: 10.1002/acr.21691.Murray SG, Yazdany J, Kaiser R, et al. Cardiovascular disease and cognitive dysfunction in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012 Sep;64(9):1328-33. doi: 10.1002/acr.21691.Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997 Mar 1;145(5):408-15.Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997 Mar 1;145(5):408-15.Nurmohamed MT, van der Horst-Bruinsma I, Maksymowych WP. Cardiovascular and cerebrovascular diseases in ankylosing spondylitis: current insights. Curr Rheumatol Rep. 2012 Oct;14(5):415-21. doi: 10.1007/s11926-012-0270-6.Nurmohamed MT, van der Horst-Bruinsma I, Maksymowych WP. Cardiovascular and cerebrovascular diseases in ankylosing spondylitis: current insights. Curr Rheumatol Rep. 2012 Oct;14(5):415-21. doi: 10.1007/s11926-012-0270-6.Essers I, Stolwijk C, Boonen A, et al. Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study. Ann Rheum Dis. 2016 Jan;75(1):203-9. doi: 10.1136/annrheumdis-2014-206147.Essers I, Stolwijk C, Boonen A, et al. Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study. Ann Rheum Dis. 2016 Jan;75(1):203-9. doi: 10.1136/annrheumdis-2014-206147.Morris SJ, Wasko MC, Antohe JL, et al. Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2011 Apr;63(4):530-4. doi: 10.1002/acr.20393.Morris SJ, Wasko MC, Antohe JL, et al. Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2011 Apr;63(4):530-4. doi: 10.1002/acr.20393.Solomon DH, Massarotti E, Garg R, et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011 Jun 22;305(24):2525-31. doi: 10.1001/jama.2011.878Solomon DH, Massarotti E, Garg R, et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011 Jun 22;305(24):2525-31. doi: 10.1001/jama.2011.878Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017 Jan;76(1):17-28. doi: 10.1136/annrheumdis-2016-209775.Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017 Jan;76(1):17-28. doi: 10.1136/annrheumdis-2016-209775.Van Staa TP, Geusens P, Bijlsma JW, et al. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006 Oct;54(10):3104-12.Van Staa TP, Geusens P, Bijlsma JW, et al. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006 Oct;54(10):3104-12.Bultink IE, Lems WF. Lupus and fractures. Curr Opin Rheumatol. 2016 Jul;28(4): 426-32. doi: 10.1097/B0R.0000000000000290Bultink IE, Lems WF. Lupus and fractures. Curr Opin Rheumatol. 2016 Jul;28(4): 426-32. doi: 10.1097/B0R.0000000000000290Kanis JA, Oden A, Johansson H, et al. FRAX and its applications to clinical prac-tice. Bone. 2009 May;44(5):734-43. doi: 10.1016/j.bone.2009.01.373.Kanis JA, Oden A, Johansson H, et al. FRAX and its applications to clinical prac-tice. Bone. 2009 May;44(5):734-43. doi: 10.1016/j.bone.2009.01.373.Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009;11(3):229. doi: 10.1186/ar2669.Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009;11(3):229. doi: 10.1186/ar2669.England BR, Sayles H, Michaud K, et al. Cause-specific mortality in male US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016 Jan;68(1):36-45. doi: 10.1002/acr.22642.England BR, Sayles H, Michaud K, et al. Cause-specific mortality in male US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016 Jan;68(1):36-45. doi: 10.1002/acr.22642.Sparks JA, Chang SC, Liao KP, et al. Rheumatoid arthritis and mortality among women during 36 years of prospective followup: results from the nurses' health study. Arthritis Care Res (Hoboken). 2016 Jun;68(6): 753-62. doi: 10.1002/acr.22752.Sparks JA, Chang SC, Liao KP, et al. Rheumatoid arthritis and mortality among women during 36 years of prospective followup: results from the nurses' health study. Arthritis Care Res (Hoboken). 2016 Jun;68(6): 753-62. doi: 10.1002/acr.22752.Toms TE, Panoulas VF, Douglas KM, et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? Ann Rheum Dis. 2010 Apr;69(4):683-8. doi: 10.1136/ard.2009.115717.Toms TE, Panoulas VF, Douglas KM, et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? Ann Rheum Dis. 2010 Apr;69(4):683-8. doi: 10.1136/ard.2009.115717.Armagan B, Sari A, Erden A, et al. Starting of biological disease modifying antirheumatic drugs may be postponed in rheumatoid arthritis patients with multimorbidity: Single center real life results. Medicine (Baltimore). 2018 Mar;97(13):e9930. doi: 10.1097/MD.0000000000009930.Armagan B, Sari A, Erden A, et al. Starting of biological disease modifying antirheumatic drugs may be postponed in rheumatoid arthritis patients with multimorbidity: Single center real life results. Medicine (Baltimore). 2018 Mar;97(13):e9930. doi: 10.1097/MD.0000000000009930.Costa L, Caso F, Atteno M, et al. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol. 2014 Jun;33(6):833-9.Costa L, Caso F, Atteno M, et al. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol. 2014 Jun;33(6):833-9.Dixon WG, Watson KD, Lunt M, et al; British Society for Rheumatology Biologics Register Control Centre Consortium, British Society for Rheumatology Biologics Register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to antitumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007 Sep;56(9):2905-12.Dixon WG, Watson KD, Lunt M, et al; British Society for Rheumatology Biologics Register Control Centre Consortium, British Society for Rheumatology Biologics Register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007 Sep;56(9):2905-12.Radner H, Yoshida K, Frits M, et al. The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs. Rheumatology (Oxford). 2015 Nov;54(11):2076-84. doi: 10.1093/rheumatology/kev239.Radner H, Yoshida K, Frits M, et al. The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs. Rheumatology (Oxford). 2015 Nov;54(11):2076-84. doi: 10.1093/rheumatology/kev239.Eder L, Thavaneswaran A, Chandran V, et al. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis. 2015 May;74(5): 813-7. doi: 10.1136/annrheumdis-2013-204448.Eder L, Thavaneswaran A, Chandran V, et al. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis. 2015 May;74(5): 813-7. doi: 10.1136/annrheumdis-2013-204448.Radner H, Yoshida K, Tedeschi SK, et al. Different perception of disease activity in Multimorbid rheumatoid arthritis patients [abstract]. Arthritis Rheum. 2015;67(Suppl 10): abstract 3258.Radner H, Yoshida K, Tedeschi SK, et al. Different perception of disease activity in Multimorbid rheumatoid arthritis patients [abstract]. Arthritis Rheum. 2015;67(Suppl 10): abstract 3258.Rupp I, Boshuizen HC, Jacobi CE, et al. Comorbidity in patients with rheumatoid arthritis: effect on health-related quality of life. J Rheumatol. 2004 Jan;31(1):58-65.Rupp I, Boshuizen HC, Jacobi CE, et al. Comorbidity in patients with rheumatoid arthritis: effect on health-related quality of life. J Rheumatol. 2004 Jan;31(1):58-65.Radner H, Smolen JS, Aletaha D. Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. Rheumatology (Oxford). 2011 Feb;50(2):381-8. doi: 10.1093/rheumatology/keq334. Epub 2010 Oct 29.Radner H, Smolen JS, Aletaha D. Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. Rheumatology (Oxford). 2011 Feb;50(2):381-8. doi: 10.1093/rheumatology/keq334. Epub 2010 Oct 29.Radner H, Smolen JS, Aletaha D. Impact of comorbidity on physical function in patients with rheumatoid arthritis. Ann Rheum Dis. 2010 Mar;69(3):536-41. doi: 10.1136/ard.2009.118430. Epub 2009 Oct 12.Radner H, Smolen JS, Aletaha D. Impact of comorbidity on physical function in patients with rheumatoid arthritis. Ann Rheum Dis. 2010 Mar;69(3):536-41. doi: 10.1136/ard.2009.118430. Epub 2009 Oct 12.Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83Susser SR, McCusker J, Belzile E. Comorbidity information in older patients at an emergency visit: self-report vs. administrative data had poor agreement but similar predictive validity. J Clin Epidemiol. 2008 May; 61(5):511-5. doi: 10.1016/j.jclinepi.2007.07.009. Epub 2008 Jan 7.Susser SR, McCusker J, Belzile E. Comorbidity information in older patients at an emergency visit: self-report vs. administrative data had poor agreement but similar predictive validity. J Clin Epidemiol. 2008 May; 61(5):511-5. doi: 10.1016/j.jclinepi.2007.07.009. Epub 2008 Jan 7.Radner H, Smolen JS, Aletaha D. Impact of comorbidity on physical function in patients with rheumatoid arthritis. Ann Rheum Dis. 2010 Mar;69(3):536-41. doi: 10.1136/ard.2009.118430. Epub 2009 Oct 12.Radner H, Smolen JS, Aletaha D. Impact of comorbidity on physical function in patients with rheumatoid arthritis. Ann Rheum Dis. 2010 Mar;69(3):536-41. doi: 10.1136/ard.2009.118430. Epub 2009 Oct 12.Gabriel SE, Crowson CS, O'Fallon WM. A comparison of two comorbidity instruments in arthritis. J Clin Epidemiol. 1999 Dec;52(12): 1137-42. doi:10.1016/S0895-4356(99)00124-9Gabriel SE, Crowson CS, O'Fallon WM. A comparison of two comorbidity instruments in arthritis. J Clin Epidemiol. 1999 Dec;52(12): 1137-42. doi:10.1016/S0895-4356(99)00124-9Michelsen B, Kristianslund EK, Sexton J, et al. Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. Ann Rheum Dis. 2017 Nov;76(11): 1906-1910. doi: 10.1136/annrheumdis-2017-211284. Epub 2017 Jul 21.Michelsen B, Kristianslund EK, Sexton J, et al. Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. Ann Rheum Dis. 2017 Nov;76(11): 1906-1910. doi: 10.1136/annrheumdis-2017-211284. Epub 2017 Jul 21.Groll DL, To T, Bombardier C, Wright JG. The development of a comorbidity index with physical function as the outcome. J J Clin Epidemiol. 2005 Jun;58(6):595-602. doi:10.1016/jjclinepi.2004.10.018Groll DL, To T, Bombardier C, Wright JG. The development of a comorbidity index with physical function as the outcome. J J Clin Epidemiol. 2005 Jun;58(6):595-602. doi:10.1016/jjclinepi.2004.10.018Linn BS, Linn MW, Gurel L. Cumulative Illness Rating Scale. J Am Geriatr Soc. 1968 May;16(5):622-6.Linn BS, Linn MW, Gurel L. Cumulative Illness Rating Scale. J Am Geriatr Soc. 1968 May;16(5):622-6.Parmelee PA, Thuras PD, Katz IR, Lawton MP. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc. 1995 Feb;43(2): 130-7.Parmelee PA, Thuras PD, Katz IR, Lawton MP. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc. 1995 Feb;43(2): 130-7.Salvi F, Miller MD, Grilli A, et al. A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc. 2008 Oct;56(10):1926-31. doi: 10.1111/j.1532-5415.2008.01935.x.Salvi F, Miller MD, Grilli A, et al. A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc. 2008 Oct;56(10):1926-31. doi: 10.1111/j.1532-5415.2008.01935.x.Fortin M, Hudon C, Dubois MF, et al. Comparative assessment of three different indices of multimorbidity for studies on health-related quality of life. Health Qual Life Outcomes. 2005 Nov 23;3:74Fortin M, Hudon C, Dubois MF, et al. Comparative assessment of three different indices of multimorbidity for studies on health-related quality of life. Health Qual Life Outcomes. 2005 Nov 23;3:74Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007 Oct;21(5):885-906. doi:10.1016/j.berh.2007.06.002Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007 Oct;21(5):885-906. doi:10.1016/j.berh.2007.06.002England BR, Sayles H, Mikuls TR, et al. Validation of the rheumatic disease comorbidity index. Arthritis Care Res (Hoboken). 2015 May;67(6):865-72. doi: 10.1002/acr.22456.England BR, Sayles H, Mikuls TR, et al. Validation of the rheumatic disease comorbidity index. Arthritis Care Res (Hoboken). 2015 May;67(6):865-72. doi: 10.1002/acr.22456.Radner H, Yoshida K, Mjaavatten MD, et al. Development of a multimorbidity index: impact on quality of life using a rheumatoid arthritis cohort. Semin Arthritis Rheum. 2015 Oct;45(2):167-73. doi: 10.1016/j.semarthrit.2015.06.010. Epub 2015 Jun 19.Radner H, Yoshida K, Mjaavatten MD, et al. Development of a multimorbidity index: impact on quality of life using a rheumatoid arthritis cohort. Semin Arthritis Rheum. 2015 Oct;45(2):167-73. doi: 10.1016/j.semarthrit.2015.06.010. Epub 2015 Jun 19.Radner H, Yoshida K, Frits M, et al. The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying antirheumatic drugs. Rheumatology (Oxford). 2015 Nov;54(11):2076-84. doi: 10.1093/rheumatology/kev239. Epub 2015 Jul 10.Radner H, Yoshida K, Frits M, et al. The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying antirheumatic drugs. Rheumatology (Oxford). 2015 Nov;54(11):2076-84. doi: 10.1093/rheumatology/kev239. Epub 2015 Jul 10.Crepaldi G, Scire CA, Carrara G, et al. Cardiovascular comorbidities relate more than others with disease activity in rheumatoid arthritis. PLoSOne. 2016 Jan 12;11(1): e0146991. doi: 10.1371/journal.pone.0146991. eCollection 2016.Crepaldi G, Scire CA, Carrara G, et al. Cardiovascular comorbidities relate more than others with disease activity in rheumatoid arthritis. PLoSOne. 2016 Jan 12;11(1): e0146991. doi: 10.1371/journal.pone.0146991. eCollection 2016.Baillet A, Gossec L, Carmona L, et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. Ann Rheum Dis. 2016 Jun;75(6):965-73. doi: 10.1136/annrheumdis-2016-209233.Baillet A, Gossec L, Carmona L, et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. Ann Rheum Dis. 2016 Jun;75(6):965-73. doi: 10.1136/annrheumdis-2016-209233.Radner H, Chatzidionysiou K, Nikiphorou E, et al. 2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. Ann Rheum Dis. 2018 Apr; 77(4):476-479. doi: 10.1136/annrheumdis-2017-212256.Radner H, Chatzidionysiou K, Nikiphorou E, et al. 2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. Ann Rheum Dis. 2018 Apr; 77(4):476-479. doi: 10.1136/annrheumdis-2017-212256.

The authors declare that there are no conflicts of interest present.